Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Shareholders' Equity

v3.20.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated deficit
Ordinary A Shares (pre-merger - BiomX Ltd.),
Preferred A Shares (pre-merger - BiomX Ltd.),
Preferred B Shares (pre-merger - BiomX Ltd.),
Total
Balance at Dec. 31, 2017 [1] $ 20,419 $ (8,889) [1] [1] $ 11,530
Balance, shares at Dec. 31, 2017 1,580,159     696,774 4,514,841    
Issuance of shares [2] 43,040   [1] $ 1 43,042
Issuance of shares, shares [2]       3,028,990 5,170,357  
Conversion of Ordinary to Ordinary A Shares [1] [1]
Conversion of Ordinary to Ordinary A Shares, shares 696,774     (696,774)      
Share-based payment 951 951
Exercise of options [1]
Exercise of options, shares 30,938            
Net loss (12,720) (12,720)
Balance at Dec. 31, 2018 [1]   (21,609) $ 1 $ 1 42,803
Balance, shares at Dec. 31, 2018 2,307,871       7,543,831 5,170,357  
Issuance of shares [3] 1,800 [1] 1,800
Issuance of shares, shares [3]         308,628  
Effect of reverse recapitalization transaction $ 2 59,397 $ (1) $ (1) 59,397
Effect of reverse recapitalization transaction, shares 20,486,082       (7,543,831) (5,478,985)  
Acquisition of treasury stock [1] (19) (19)
Acquisition of treasury stock, shares (5,700)            
Share-based payment 938 938
Exercise of options [1] 100 100
Exercise of options, shares 74,582            
Net loss (20,563) (20,563)
Balance at Dec. 31, 2019 $ 2 $ 126,626 $ (42,172) $ 84,456
Balance, shares at Dec. 31, 2019 22,862,835            
[1] Less than $1 thousand.
[2] Net of issuance expenses in amount of $73 thousand.
[3] Net of issuance expenses in amount of $114 thousand.